Loading...
•
Dec 31, 2024
Adaptive Biotechnologies Q4 2024 Earnings Report
Adaptive Biotechnologies reported its fourth quarter and full year 2024 financial results, showing growth in revenue and a reduction in net loss and adjusted EBITDA loss compared to the previous year.
Key Takeaways
Adaptive Biotechnologies reported a revenue of $47.5 million for the fourth quarter of 2024, a 4% increase from the prior year. The company's net loss significantly decreased to $33.7 million from $69.5 million in the same period last year, and adjusted EBITDA loss improved to $16.4 million from $24.7 million.
Fourth quarter 2024 revenue was $47.5 million, a 4% increase from the prior year.
Net loss for the fourth quarter of 2024 was $33.7 million, a significant improvement from $69.5 million in Q4 2023.
Adjusted EBITDA (non-GAAP) was a loss of $16.4 million, an improvement from a loss of $24.7 million in Q4 2023.
clonoSEQ® test volume increased 34% to 20,945 tests delivered in the fourth quarter of 2024.
Revenue by Segment
Forward Guidance
Adaptive Biotechnologies expects full year 2025 revenue for the MRD business to be between $175 million and $185 million, with total company operating expenses between $340 million and $350 million, and total company cash burn between $60 million and $70 million.
Positive Outlook
- Expected full year MRD business revenue between $175 million and $185 million.
- Focus on achieving profitability in MRD.
- Advancing therapeutics pipeline in Immune Medicine.
- Maintaining a durable cash position to support sustainable, long-term growth.
- No revenue guidance provided for Immune Medicine business, suggesting focus on MRD.
Challenges Ahead
- No revenue guidance provided for the Immune Medicine business.
- Expected full year total company operating expenses between $340 million and $350 million.
- Expected full year total company cash burn between $60 million and $70 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...